Five recent Parkinson’s disease drug target discoveries
This article highlights five of the latest findings that could be used in the development or design of new therapies to treat Parkinson’s disease.
List view / Grid view
This article highlights five of the latest findings that could be used in the development or design of new therapies to treat Parkinson’s disease.
The UK Brain Banks Network has been enhanced to include genomic data, which can be accessed by researchers worldwide.
New research is the first to link maladaptive changes in calcium transport by mitochondria to the progression of Alzheimer's disease.
It has been discovered that Id4 controls whether stem cells enter cell division and may be relevant for treating neurodegenerative disease.
MSD and the Francis Crick Institute will work together on a project to identify disease targets for motor neuron disease.
A study has discovered the regulating process behind cell autophagy which could aid in the development of neurodegenerative disease treatments.
Researchers have found that the presence of microglia brain cells allowed plaques to form in the brains of rodents, leading to Alzheimer’s disease.
A study has discovered a molecule key in neuronal growth that could be used as a drug target to treat anxiety-related diseases.
A team has developed a technique for identifying pluripotent stem cells that could help research on transplantation medicine.
A study has used EEG to investigate the neuron networks that act abnormally in the condition, providing a significant step in the search for treatments.
A review has been published by experts in neurodegeneration research, detailing six ways to improve dementia research. This article investigates one of these suggestions, focusing on how we can improve drug target identification.
Researchers have discovered that the VPS35 molecule can be utilised in preventing neurodegenerative disorders.
A trial has begun in the US for the ENT-01 therapy treatment of Parkinson’s, with the first patient enrolled.
A new study found that betaine supplementations given to mice reduced schizophrenic behaviours, indicating a drug target.
A new study has found an enzyme in the brains of mice models which induces Parkinson’s, suggesting future drug target.